Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Rian Dickstein is an Urologist in Baltimore, Maryland. Dr. Dickstein is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Hydronephrosis, Ureteroscopy, and Nephrectomy. Dr. Dickstein is currently accepting new patients.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer. Dr. Pienta is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Peter Filderman is an Urologist in Baltimore, Maryland. Dr. Filderman is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Urinary Tract Infection in Children, Ureteroscopy, and Bladder Reconstruction.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Johnson is a genitourinary medical oncologist who specializes in treating patients with bladder cancer and upper tract urothelial carcinoma. He is a member of the Greenberg Bladder Cancer Institute. He obtained his M.D. and Ph.D. degrees from the Medical College of Georgia, where he completed his residency in Internal Medicine. He then completed his medical oncology fellowship and did additional postdoctoral research at Johns Hopkins before joining the faculty. He has an active laboratory which focuses on optimizing bladder cancer preclinical models, studying mechanisms of bladder cancer progression, elucidating biomarkers that correlate with bladder cancer survival and response to treatment, and testing immunotherapies in bladder cancer preclinical models. His research has been funded by an ASCO Young Investigator Award, an AACR-BMS Fellowship for Young Investigators in Translational Immuno-oncology, a Harry J. Lloyd Charitable Trust Career Development Award, a Bladder Cancer Advocacy Network Young Investigator Award, and a Department of Defense Career Development Award. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, and Urothelial Cancer.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Arthur Burnett is an Urologist in Baltimore, Maryland. Dr. Burnett is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Priapism, Erectile Dysfunction (ED), Peyronie Disease, Prostatectomy, and Penectomy.

Eric Christenson is an Oncologist in Baltimore, Maryland. Dr. Christenson is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Cholangiocarcinoma (Bile Duct Cancer).

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.

Mohummad Siddiqui is an Urologist in Baltimore, Maryland. Dr. Siddiqui is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Vasectomy, and Nephrectomy. Dr. Siddiqui is currently accepting new patients.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

Dr. Edward Wright is an associate professor of urology at the Johns Hopkins School of Medicine. He serves as the Director of Urology at the Johns Hopkins Bayview Medical Center. His clinical and research interests are in male and female urinary incontinence, complex voiding dysfunction and pelvic genitourinary reconstructive surgery. His specialty has less to do with surgical removal and more with mending urological body parts and restoring functionality in them. His passion for Johns Hopkins lies in the fact that it is the type of place where things can be done, and patients’ questions can be answered and solutions to their problems can be found through all of the resources Johns Hopkins has to offer. Dr. Wright earned his M.D. from Dartmouth Medical School in New Hampshire. He completed his residency in urology at The Presbyterian Hospital in the City of New York and performed a fellowship in Urogynecology at Duke University School of Medicine. Dr. Wright is a member of the American Urologic Association and the Mid-Atlantic Section of American Urologic Association as well as the Society for Urodynamics and Female Urology. He has been recognized with a number of awards including Winner of the Urology Chief Resident's debate New York section of the American Urologic Society at the The New York Academy of Medicine. Dr. Wright is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Neurogenic Bladder, Stress Urinary Incontinence, Urinary Incontinence, Ureteroscopy, and Bladder Reconstruction.

Dr. Marisa Clifton is the Director of Women’s Health at the Brady Urological Institute. She is fellowship trained. As a leader in the field of female urology, her clinical expertise includes surgical and nonsurgical treatment of pelvic organ prolapse, stress urinary incontinence, urgency urinary incontinence, urinary fistulas, genitourinary reconstruction and urethral diverticula. Dr. Clifton is also an Assistant Professor of Urology at the Johns Hopkins School of Medicine and serves as the Director of Robotic Education. In addition, she serves as Vice President of Medical Affairs at Johns Hopkins Bayview Medical Center. She also serves as Associate Chief Medical Officer of The Johns Hopkins Hospital. Her research interests include medical education and clinical outcomes after surgery. Dr. Clifton received her medical degree from the Johns Hopkins University School of Medicine and completed her residency in urology at the Mayo Clinic in Rochester, Minnesota. She completed her fellowship in Female Pelvic Medicine and Reconstructive Surgery at The Cleveland Clinic in Cleveland, Ohio. Dr. Clifton is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Urinary Incontinence, Obstructive Uropathy, Neurogenic Bladder, Sacral Nerve Stimulation, and Hormone Replacement Therapy (HRT).

Dr. Andrew J. Cohen is an Associate Professor of Urology at Johns Hopkins. He serves as the Division Director of Benign Urology and Director of Advanced Practice Providers at the Johns Hopkins Brady Urological Institute. He has a robust clinical practice focusing on complex genitourinary reconstruction. In particular, he has interest in the management of erectile dysfunction, urinary incontinence, stricture diseases of the urinary system, peyronie's disease, genital skin conditions, buried penis, urinary diversion, and other benign urologic conditions. He has extensive experience in robotic surgery. He also focuses on issues pertinent to cancer survivorship in men. He is well equipped to perform novel minimally invasive procedures such as endoscopic urethroplasty and robotic buccal ureteroplasty. He has an extensive research portfolio, with particular concentration in outcomes and safety research. Dr. Cohen received dual B.S. degrees summa cum laude from the University of Florida in Chemistry and Chemical Engineering, followed by an MD from the University of Chicago where he was inducted into the Alpha Omega Alpha Honor Society. His urologic training was pursued at the University of Chicago. Furthermore, he completed a fellowship in Genitourinary Reconstruction and Trauma at the University of California, San Francisco. Among many honors, he was invited to join the Trauma and Urologic Reconstructive Network of Surgeons in 2025. He was a also a recipient of the 'Rising Star' Award from the Society of Genitouinary Reconstructive Surgeons in 2025. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Urethral Stricture, Hydronephrosis, Obstructive Uropathy, Prostatectomy, and Lithotripsy.